{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T03:18:51Z","timestamp":1789960731908,"version":"4.0.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-025-02678-x","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T03:06:16Z","timestamp":1744254376000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of the duration of new nasal drug interferon \u03b1-2b activity in an experimental model system"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4462-6489","authenticated-orcid":false,"given":"N.","family":"Bezdieniezhnykh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3622-0489","authenticated-orcid":false,"given":"O.","family":"Lykhova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2195-0775","authenticated-orcid":false,"given":"G.","family":"Borshchevskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6697-8077","authenticated-orcid":false,"given":"Ye.","family":"Kruglov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7840-0096","authenticated-orcid":false,"given":"M.","family":"Borshchevska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"issue":"121","key":"2678_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1046\/j.1365-2141.2003.04255.x","volume":"2","author":"W Matsui","year":"2003","unstructured":"Matsui W, Huff CA, Vala M, Barber J, Smith BD, et al. Anti-tumour activity of interferon-\u03b1 in multiple myeloma: role of interleukin 6 and tumor cell differentiation. J Haematol. 2003;2(121):251\u20138. https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04255.x.","journal-title":"J Haematol"},{"key":"2678_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40364-022-00415-y","volume":"10","author":"F Xiong","year":"2022","unstructured":"Xiong F, Wang Q, Wu GH, Liu WZ, Wang B, et al. Direct and indirect effects of IFN-\u03b12b in malignancy treatment: not only an archer but also an arrow. Biomark Res. 2022;10:69. https:\/\/doi.org\/10.1186\/s40364-022-00415-y.","journal-title":"Biomark Res"},{"key":"2678_CR3","doi-asserted-by":"publisher","DOI":"10.2174\/1568026621666210429083050","author":"Z Meng","year":"2021","unstructured":"Meng Z, Wang T, Chen L, Chen X, Li L, et al. The effect of recombinant human interferon \u03b1 nasal drops to prevent COVID-19 pneumonia for medical staff in an epidemic area. Current Topics Med Chem. 2021. https:\/\/doi.org\/10.2174\/1568026621666210429083050.","journal-title":"Current Topics Med Chem"},{"key":"2678_CR4","doi-asserted-by":"publisher","DOI":"10.34172\/jre.2021.05","volume":"7","author":"A Abdo-Cuza","year":"2021","unstructured":"Abdo-Cuza A, Castellanos-Guti\u00e9rrez R, Treto-Ramirez J, Arencibia-Larin S, G\u00f3mez-Pariente T, et al. Safety and efficacy of intranasal recombinant human interferon \u03b1 2b as prophylaxis for COVID-19 in patients on a hemodialysis program. J Renal Endocrinol. 2021;7: e05. https:\/\/doi.org\/10.34172\/jre.2021.05.","journal-title":"J Renal Endocrinol"},{"issue":"8","key":"2678_CR5","doi-asserted-by":"publisher","first-page":"6887","DOI":"10.3390\/ijms24086887","volume":"24","author":"A Kamyshnyi","year":"2023","unstructured":"Kamyshnyi A, Koval H, Kobevko O, Buchynskyi M, Oksenych V, et al. Therapeutic Effectiveness of Interferon-\u03b12b against COVID-19 with community-acquired pneumonia: the Ukrainian experience. Int J Mol Sci. 2023;24(8):6887. https:\/\/doi.org\/10.3390\/ijms24086887.","journal-title":"Int J Mol Sci"},{"key":"2678_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.967716","volume":"13","author":"N Xu","year":"2022","unstructured":"Xu N, Pan J, Sun L, Zhou C, Huang S, et al. Interferon \u03b1-2b spray shortened viral shedding time of SARS-CoV-2 Omicron variant: an open prospective cohort study. Front Immunol. 2022;13: 967716. https:\/\/doi.org\/10.3389\/fimmu.2022.967716.","journal-title":"Front Immunol"},{"issue":"8","key":"2678_CR7","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1080\/17425247.2023.2263363","volume":"20","author":"F Sonvico","year":"2023","unstructured":"Sonvico F, Colombo G, Quarta E, Guareschi F, Banella S, et al. Nasal delivery as a strategy for the prevention and treatment of COVID-19. Expert Opin Drug Deliv. 2023;20(8):1115\u201330. https:\/\/doi.org\/10.1080\/17425247.2023.2263363.","journal-title":"Expert Opin Drug Deliv"},{"key":"2678_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/9780470649367","volume-title":"Culture of animal cells: a manual of basic technique and specialized applications","author":"R Ian Freshney","year":"2010","unstructured":"Ian Freshney R. Culture of animal cells: a manual of basic technique and specialized applications. Wiley; 2010. https:\/\/doi.org\/10.1002\/9780470649367."},{"issue":"3","key":"2678_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1053\/tvjl.1998.0303","volume":"157","author":"GJ Letchworth","year":"1999","unstructured":"Letchworth GJ, Rodriguez LL, Del Cbarrera J. Vesicular stomatitis. Vet J. 1999;157(3):239\u201360. https:\/\/doi.org\/10.1053\/tvjl.1998.0303.","journal-title":"Vet J"},{"key":"2678_CR10","first-page":"453","volume-title":"Virology","author":"FE Fields","year":"2013","unstructured":"Fields FE, Martin M. Virology. Philadelphia: Wolters Kluwer Health\/Lippincott Williams & Wilkins; 2013. p. 453\u201390."},{"issue":"4","key":"2678_CR11","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1177\/0194599820933170","volume":"163","author":"TS Higgins","year":"2020","unstructured":"Higgins TS, Wu AW, Illing EA, Sokoloski KJ, Weaver BA, et al. Intranasal antiviral drug delivery and coronavirus disease 2019 (COVID-19): a state of the art review. Otolaryngol Head Neck Surg. 2020;163(4):682\u201394. https:\/\/doi.org\/10.1177\/0194599820933170.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"2","key":"2678_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.2174\/1574885518666230727100812","volume":"19","author":"R Jino Affrald","year":"2024","unstructured":"Jino Affrald R, Narayan S. Intranasal drug delivery of antiviral agents - a revisit and way forward. Current Drug Therapy. 2024;19(2):130\u201350. https:\/\/doi.org\/10.2174\/1574885518666230727100812.","journal-title":"Current Drug Therapy"},{"issue":"11","key":"2678_CR13","doi-asserted-by":"publisher","first-page":"6364","DOI":"10.1111\/1462-2920.15769","volume":"23","author":"H Br\u00fcssow","year":"2021","unstructured":"Br\u00fcssow H. Clinical trials with antiviral drugs against COVID -19: some progress and many shattered hopes. Environ Microbiol. 2021;23(11):6364\u201376. https:\/\/doi.org\/10.1111\/1462-2920.15769.","journal-title":"Environ Microbiol"},{"key":"2678_CR14","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/S0140-6736(22)00519-0","volume":"399","author":"Consortium WHO Solidarity Trial","year":"2022","unstructured":"Consortium WHO Solidarity Trial. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO solidarity randomised trial and updated meta-analyses. Lancet. 2022;399:1941\u201353.","journal-title":"Lancet"},{"issue":"10259","key":"2678_CR15","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(20)32013-4","volume":"396","author":"Recovery Collaborative Group","year":"2020","unstructured":"Recovery Collaborative Group. Lopinavir\u2013ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet. 2020;396(10259):1345\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(20)32013-4.","journal-title":"The Lancet"},{"issue":"5","key":"2678_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41579-022-00713-0","volume":"20","author":"MM Lamers","year":"2022","unstructured":"Lamers MM, Haagmans BL. SARS-CoV-2 pathogenesis. Nat Rev Microbiol. 2022;20(5):270\u201384. https:\/\/doi.org\/10.1038\/s41579-022-00713-0.","journal-title":"Nat Rev Microbiol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02678-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-025-02678-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02678-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T15:03:18Z","timestamp":1744297398000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-025-02678-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2678"],"URL":"https:\/\/doi.org\/10.1186\/s12985-025-02678-x","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"5 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no potential competing interests with respect to the research, authorship, or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}